Monoclonal Antibodies (mAbs) Market Market Size, Status, Top Players, Trends and Forecast to 2024
Monoclonal Antibodies (mAbs) Market research report is provided for the current market along with growth history, competitive landscape evaluation and most important region’s development status.
(EMAILWIRE.COM, October 25, 2018 ) There has been an increase in the research and development activities in the field of Monoclonal Antibodies (mAbs) Market. Several biomedical and technological advances in genetic engineering and next generation genome sequencing have fuelled the growth of the monoclonal antibody market. Also, multiple new targets have been identified during preclinical research, which has led to the development and production of newer monoclonal antibodies by using various cytotechnological methodologies. In addition to this, favorable government initiatives to enable cost-effective production of monoclonal antibodies would give impetus to the monoclonal antibodies market growth. Also, pre-defined guidelines by regulatory bodies would ensure the safe, effective and high-quality manufacturing of monoclonal antibodies Recently, the European Commission approved the first biosimilar mAb Celltrion’s Truxima (biosimilar rituximab), thereby boding well for its potential approval in the U.S.
Request for Sample Copy of this research report @
http://bit.ly/2R8QSrL
According to a new study published by Polaris Market Research the Monoclonal Antibodies (mAbs) Market is anticipated to reach over USD 148.9 billion by 2026.
In 2017, by indication, the cancer segment dominated the market in terms of revenue, wherein fully-human monoclonal antibodies held a major share of the market. In terms of geography, North America accounted for the majority share in the Monoclonal Antibodies (mAbs) Market.
Monoclonal Antibodies (mAbs) Market is mainly driven by an active pipeline, wherein many monoclonal antibodies are at the different stages of drug development. In addition, increased in research and development, favourable government policies and rising prevalence of cancer and other chronic diseases supplement the market growth. The other factors that augment that market growth include the increasing the demand for personalized medicine and rising awareness among medical professional and patients about the latest medical therapies. Moreover, emerging targets such as central nervous system disorders, price correction and new delivery strategies for monoclonal antibodies provide opportunities for market growth in the near future.
Enquire Before Buying this research report @
http://bit.ly/2RbdNmu
Following are the Top Key Players in Monoclonal Antibodies (mAbs) Market: -
Pfizer, Inc.
GlaxoSmithKline PLC
Novartis AG
Merck & Co. Inc.
Eli Lily & Co.
AstraZeneca
Amgen, Inc.
Abbott Laboratories
Thermo Fisher Scientific Inc.
Bistro-Myers Squibb. Mylan N.V.
Daiichi Sankyo Company Ltd.
Bayer AG
Hoffmann-La Roche Ltd.
Novo Nordisk A/S.
The widespread and rapidly increasing prevalence of cancer and other chronic diseases have resulted in the soaring demand of biological medicines, thereby augmenting the growth of monoclonal antibodies. Furthermore, several other monoclonal antibodies used in treatment of deadly infections such as HIV/AIDS, Ebola and Zika viral disease are in various phases of clinical trials. Also, high spending power of patients in developed countries, increasing disposable incomes in developing countries and better healthcare facilities further facilitate market growth. Going forward, increasing awareness about the latest medical therapies among medical professional and patients, and increasing utilization of monoclonal antibodies in treatment regimens is anticipated to propel the Monoclonal Antibodies (mAbs) Market growth.
TOC of Monoclonal Antibodies (mAbs) Market:
Chapter 1. Overview and Scope
Chapter 2. Market Summary
Chapter 3. Monoclonal Antibodies (mAbs) Market Size and Forecast
Chapter 4. Dynamics and Segmentation
Chapter 5. Detailed Insight on Key Company
Chapter 6. Research Methodology and Reference
Chapter 7. Competitive Landscape
TOC Continued…...!!!
Request for Sample Copy of this research report @
http://bit.ly/2R8QSrL
According to a new study published by Polaris Market Research the Monoclonal Antibodies (mAbs) Market is anticipated to reach over USD 148.9 billion by 2026.
In 2017, by indication, the cancer segment dominated the market in terms of revenue, wherein fully-human monoclonal antibodies held a major share of the market. In terms of geography, North America accounted for the majority share in the Monoclonal Antibodies (mAbs) Market.
Monoclonal Antibodies (mAbs) Market is mainly driven by an active pipeline, wherein many monoclonal antibodies are at the different stages of drug development. In addition, increased in research and development, favourable government policies and rising prevalence of cancer and other chronic diseases supplement the market growth. The other factors that augment that market growth include the increasing the demand for personalized medicine and rising awareness among medical professional and patients about the latest medical therapies. Moreover, emerging targets such as central nervous system disorders, price correction and new delivery strategies for monoclonal antibodies provide opportunities for market growth in the near future.
Enquire Before Buying this research report @
http://bit.ly/2RbdNmu
Following are the Top Key Players in Monoclonal Antibodies (mAbs) Market: -
Pfizer, Inc.
GlaxoSmithKline PLC
Novartis AG
Merck & Co. Inc.
Eli Lily & Co.
AstraZeneca
Amgen, Inc.
Abbott Laboratories
Thermo Fisher Scientific Inc.
Bistro-Myers Squibb. Mylan N.V.
Daiichi Sankyo Company Ltd.
Bayer AG
Hoffmann-La Roche Ltd.
Novo Nordisk A/S.
The widespread and rapidly increasing prevalence of cancer and other chronic diseases have resulted in the soaring demand of biological medicines, thereby augmenting the growth of monoclonal antibodies. Furthermore, several other monoclonal antibodies used in treatment of deadly infections such as HIV/AIDS, Ebola and Zika viral disease are in various phases of clinical trials. Also, high spending power of patients in developed countries, increasing disposable incomes in developing countries and better healthcare facilities further facilitate market growth. Going forward, increasing awareness about the latest medical therapies among medical professional and patients, and increasing utilization of monoclonal antibodies in treatment regimens is anticipated to propel the Monoclonal Antibodies (mAbs) Market growth.
TOC of Monoclonal Antibodies (mAbs) Market:
Chapter 1. Overview and Scope
Chapter 2. Market Summary
Chapter 3. Monoclonal Antibodies (mAbs) Market Size and Forecast
Chapter 4. Dynamics and Segmentation
Chapter 5. Detailed Insight on Key Company
Chapter 6. Research Methodology and Reference
Chapter 7. Competitive Landscape
TOC Continued…...!!!
Contact Information:
Polaris Market Research
Neel
Tel: +1-646-568-9980
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Polaris Market Research
Neel
Tel: +1-646-568-9980
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results